Cytokine Modulation in Tumor Immunology

Cytokines are pivotal mediators in the tumour microenvironment, orchestrating both antitumour immunity and tumour-promoting inflammation. Pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-7 (IL-7) can enhance cytotoxic T-cell activation, drive memory T-cell proliferation and support the efficacy of immune checkpoint blockade. In contrast, immunosuppressive cytokines—including interleukin-10 (IL-10) and transforming growth factor-β (TGF-β)—foster regulatory cell populations, dampen antigen presentation and facilitate immune escape. Recent advances focus on rebalancing these opposing signals: attenuating suppressive pathways or augmenting stimulatory cascades to tip the balance towards durable tumour control. Translation of these insights spans biomarker refinement for patient selection, design of cytokine-targeted biologics and integration with standard therapies to remodel the tumour milieu and enhance clinical outcomes.

Research from Nature Portfolio

A designed peptide antagonist derived from the IL-10 receptor binding region has been shown to bind with high affinity to IL-10 receptor subunits, block IL-10-mediated immunosuppression and restore macrophage and T-cell function in vitro. Conjugated to chemotherapy-loaded gold nanoparticles, this peptide enhances targeted drug delivery and potentiates cytotoxic efficacy against breast cancer cells. Studies of combined CTLA-4/PD-1 blockade reveal a critical interdependence of IL-7 and IFN-γ signalling in tumour-infiltrating T cells, whereby IFN-γ drives upregulation of the IL-7 receptor and amplifies T-cell expansion, underpinning synergistic eradication of established tumours. Parallel work demonstrates that the baseline ratio of IFN-γ to IL-10 expression in peripheral blood mononuclear cells stratifies patient response to PD-1 checkpoint inhibitors in advanced melanoma, offering a simple, blood-based biomarker to optimise immunotherapy regimens.

Cytokine Modulation in Tumor Immunology publication trend

The graph below shows the total number of articles in cytokine modulation in tumor immunology across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokine: A small, secreted protein that regulates immune cell communication and inflammatory responses within tissues.

Tumour microenvironment (TME): The complex milieu of cancer cells, stromal elements, immune cells, blood vessels and signalling molecules surrounding a tumour.

Immunosuppression: The process by which regulatory factors or cells inhibit the activation or effector functions of immune cells.

Immune checkpoint: A regulatory pathway in T cells that modulates immune responses, often exploited by tumours to evade immune attack.

Immune checkpoint blockade: Therapeutic inhibition of checkpoint receptors or ligands to restore antitumour T-cell activity.

Immunomodulation: The targeted enhancement or suppression of specific immune pathways to achieve a therapeutic effect.

References

1. Targeting inflammation as cancer therapy. Journal of Hematology & Oncology (2024).
2. A peptide derived from interleukin-10 exhibits potential anticancer activity and can facilitate cell targeting of gold nanoparticles loaded with anticancer therapeutics. Communications Chemistry (2023).
3. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications (2016).
4. Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Scientific Reports (2020).
5. Tumor secretome shapes the immune landscape during cancer progression. Journal of Experimental & Clinical Cancer Research (2025).
6. Reverting Immune Suppression to Enhance Cancer Immunotherapy. Frontiers in Oncology (2020).
7. Advances in targeting tumor microenvironment for immunotherapy. Frontiers in Immunology (2024).